4SC AG

  • WKN: 575381
  • ISIN: DE0005753818
  • Land: Deutschland

Nachricht vom 04.05.2012 | 07:30

4SC to host conference call on 10 May 2012 to present Q1 2012 financial results


4SC AG / Key word(s): Miscellaneous

04.05.2012 / 07:30


Announcement

4SC to host conference call on 10 May 2012 to present Q1 2012 financial results

Planegg-Martinsried, Germany, 4 May 2012 - 4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, will announce financial results of the 4SC Group for the first quarter of 2012 on 10 May 2012. On this day the Management Board of 4SC AG will host a conference call at 3pm CET (9am EST) to inform about the consolidated financial statements and important developments in the reporting period.

Participants can access the conference call under the following telephone numbers:

Date: 10 May 2012

Time: 3pm CET (9am EST)

Dial-in numbers:
+49 6103 485 3000 (Germany)
+44-207-153-2027 (UK)
+1-480-629-9725 (USA)
+49 6103 485 3000 (other countries)

Conference-ID: 4537583

Approximately two hours after the live presentation, an audio replay will be available at 4SC's website www.4sc.com in the section 'Investors / Events & Presentations / Conference Calls & Webcasts'.

Ends

About 4SC

The Group managed by 4SC AG (ISIN DE0005753818) discovers and develops targeted, small-molecule drugs for treating diseases with a high unmet medical need in various autoimmune and cancer indications. These drugs are intended to provide innovative treatment options that are more tolerable and efficacious than existing therapies, and provide a better quality of life. The Company's balanced pipeline comprises promising products that are in various stages of clinical development. 4SC's aim is to generate future growth and enhance its enterprise value by entering into partnerships with leading pharmaceutical companies. Founded in 1997, 4SC had 96 employees at the end of 2011. 4SC AG has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.

Legal Note

This document may contain projections or estimates relating to plans and objectives relating to our future operations, products, or services; future financial results; or assumptions underlying or relating to any such statements; each of which constitutes a forward-looking statement subject to risks and uncertainties, many of which are beyond our control. Actual results could differ materially, depending on a number of factors.

For more information please visit www.4sc.com or contact:

4SC
Jochen Orlowski, Corporate Communicatios & Investor Relations
jochen.orlowski(at)4sc.com, Tel.: +49 (0) 89 70 07 63 66

MC Services
Raimund Gabriel
raimund.gabriel(at)mc-services.eu , Tel.: +49 (0) 89 21 02 28 30

Mareike Mohr
mareike.mohr(at)mc-services.eu, Tel.: +49 (0) 89 21 02 28 40

The Trout Group (USA)
Chad Rubin
Crubin(at)troutgroup.com, Tel.: +1 646 378 2947



End of Corporate News


04.05.2012 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de



168056  04.05.2012

Anleihe im Fokus

Die DF-Anleihe 7,875%

Mit der DF Forfait AG vom wachsenden Welthandel profitieren

- Zeichnungsfrist: 21.05. bis 24.05.2013
- Laufzeit: 7 Jahre
- Kupon: 7,875% p.a.
- Volumen: bis zu 30 Mio. Euro
- ISIN: DE000A1R1CC4

Anleihe im Fokus

7,75% p.a. - Rendite aus Familienhand

– Zeichnungsstart: 23. Mai – Börse Frankfurt
– Zeichnung ab 1.000 Euro
– Laufzeit 5 Jahre
– WKN: A1TNA7
– 100% Rückzahlungskurs

GBC-Fokusbox

HELMA Eigenheimbau AG: Kaufen

Die HELMA Eigenheimbau AG präsentierte für das Geschäftsjahr 2012 Rekordwerte. Auf Basis unseres DCF-Modells haben wir einen fairen Wert je Aktie von 22,75 € ermittelt. Ausgehend vom erwarteten 2013er-EPS von 1,64 € entspricht dies einem KGV von 8,4. Das Kurspotenzial beläuft sich auf nahezu 65%.

News im Fokus

Fresenius Medical Care AG & Co. KGaA: Bekanntmachung nach Art. 4 Abs. 2 der Verordnung (EG) Nr. 2273/2003

17. Mai 2013, 17:35

Aktueller Webcast

Allianz SE

Analysts' conference call on 1Q 2013

15. Mai 2013

Aktuelle Research-Studie

Original-Research: Plan Optik AG (von GBC AG): Kaufen Plan Optik AG

17. Mai 2013